Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481966 | 1.00 | CNR1 (0.47) | CNR1SMN1; SMN2RXFP1MEN1RECQL | |
| SCHEMBL1480553 | 0.93 | CNR1 (0.46) | CNR1SMN1; SMN2RXFP1MEN1RECQL | |
| SCHEMBL1480548 | 0.93 | CNR1 (0.46) | CNR1SMN1; SMN2RXFP1MEN1RECQL | |
| SCHEMBL1480569 | 0.93 | CNR1 (0.51) | CNR1MEN1KMT2ACYSLTR2CYSLTR1 | |
| SCHEMBL1480567 | 0.93 | CNR1 (0.51) | CNR1MEN1KMT2ACYSLTR2CYSLTR1 | |
| SCHEMBL1481318 | 0.93 | FFAR4 (0.43) | CNR1MEN1RECQLKMT2ACYSLTR2 | |
| SCHEMBL1481314 | 0.93 | FFAR4 (0.43) | CNR1MEN1RECQLKMT2ACYSLTR2 | |
| SCHEMBL1480597 | 0.89 | HPGD (0.42) | CNR1CYSLTR2CYSLTR1ALDH1A1RAB9A | |
| SCHEMBL1480592 | 0.89 | HPGD (0.42) | CNR1CYSLTR2CYSLTR1ALDH1A1RAB9A | |
| SCHEMBL1481105 | 0.88 | CNR1 (0.51) | CNR1MEN1RECQLKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-1594847-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | CNR1 3369/4885SMN1; SMN2 4575/4885RXFP1 3571/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | CNR1 3369/4885SMN1; SMN2 4575/4885RXFP1 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.